@article{7f82c6ebde244206a1a3d63ea9905c17,
title = "Novel engineered nanocrystalline ultra-hydrophilic hard ceramic coatings for attachment and growth of bone marrow stromal cells",
abstract = "The interaction of cells on the surface of newly engineered nano-crystal films of stabilizer free cubic zirconia (with a hardness of 16 GPa), aluminum, titanium, tantalum, cerium oxides and silver was studied. The grain sizes of the nanocrystalline samples were determined by transmission electron microscopy (TEM) and surface roughness measured by atomic force microscopy (AFM). Both chemistry and characteristics of nano-structured surface coatings influenced the adhesion, survival and growth of mesenchymal stem cells (MSCs).",
author = "F. Namavar and Jackson, {J. D.} and Sharp, {J. G.} and S. Varma and H. Haider and C. Feschuk and Garvin, {K. L.}",
note = "Funding Information: The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research U.K. Support is also provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer Research), the National Cancer Research Institute (to The Institute of Cancer Research), Breakthrough Breast Cancer, Cancer Research UK (to AA) and the National Institute for Health Research Biomedical Research Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research). AO is recipient of a 2-year bursary from the Swiss Cancer League (No. BIL KLS-02592-02-2010). Funding Information: JdB reports receiving fee from AstraZeneca and Merck for a consultant and advisory role and grant funding from AstraZeneca and Merck for clinical research; SK reports receiving fee from AstraZeneca and Merck for a consultant and advisory role; AA and CJL report that they may benefit financially from the development of PARPis through patents held jointly with KuDOS–AstraZeneca through the Institute of Cancer Research {\textquoteleft}rewards to inventors{\textquoteright} scheme; TAY reports receiving fee from Merck for a consultant and advisory role and grant funding from Merck; SKS reports receiving grant funding from AstraZeneca for clinical research. There are no other potential conflicts of interest relevant to this manuscript. Funding Information: The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research U.K. Support is also provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer Research), the National Cancer Research Institute (to The Institute of Cancer Research), Breakthrough Breast Cancer, Cancer Research UK (to AA) and the National Institute for Health Research Biomedical Research Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research). AO is recipient of a 2-year bursary from the Swiss Cancer League (No. BIL KLS-02592-02-2010). The National Cancer Research Institute, Experimental Cancer Medicine Centre. JdB reports receiving fee from AstraZeneca and Merck for a consultant and advisory role and grant funding from AstraZeneca and Merck for clinical research; SK reports receiving fee from AstraZeneca and Merck for a consultant and advisory role; AA and CJL report that they may benefit financially from the development of PARPis through patents held jointly with KuDOS?AstraZeneca through the Institute of Cancer Research ?rewards to inventors? scheme; TAY reports receiving fee from Merck for a consultant and advisory role and grant funding from Merck; SKS reports receiving grant funding from AstraZeneca for clinical research. There are no other potential conflicts of interest relevant to this manuscript.",
year = "2006",
month = dec,
doi = "10.32604/mcb.2006.003.171",
language = "English (US)",
volume = "3",
pages = "171--172",
journal = "MCB Molecular and Cellular Biomechanics",
issn = "1556-5297",
publisher = "Sin-Chn Scientific Press",
number = "4",
}